Les Funtleyder is a Healthcare Portfolio Manager at E Squared where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. Prior to E Squared Mr. Funtleyder was the Director of Strategic Investments for Opko Health and a healthcare strategist portfolio manager for the Miller Tabak Health Care Transformation Fund (Symbol: MTHFX). He joined Miller Tabak after managing a healthcare portfolio for Provident Advisors. Before joining Provident, Les worked as a medical device analyst at UBS Warburg. He also covered Biotechnology stocks at Bigelow and company. His industry experience includes directing clinical and business research at Innovative Health Solution, a joint venture of Merck and Wyeth, and as a consultant to HMOs and hospitals for Coopers & Lybrand and Health Strategies Group. He started his healthcare career at Empire Blue Cross/Blue Shield.

Mr. Funtleyder wrote Healthcare Investing: Profiting from the New World of Pharma, Biotech, and Health Care Services, which bridges the gap between health reform, innovation and investing. He is widely quoted in the Wall Street Journal, the New York Times, and the Financial Times, and is a frequent guest on CNBC, Bloomberg, and NPR for his perspective on the healthcare sector and its constituent companies. He is also a consulting partner to Bluecloud Health and holds boardships with several healthcare companies and foundations. Les is currently at Adjunct Professor of Public Health at Columbia.

Les earned his Masters of Public Health from Columbia University Mailman School of Public Health, and studied English and Economics at Tulane University.